Differences in downstream activation of mGluR1 through glutamate between hormone sensitive versus hormone refractory tumors may explain the difference in prognostic value of mGluR1 in hormone receptor positive versus the important hormone receptor negative breast cancer subgroup30–32. This evidence concerns the gene GRM1 and breast cancer.